@article{d91971c563cd433f893b884b71a49414,
title = "Human germinal centres engage memory and naive B cells after influenza vaccination",
abstract = "Influenza viruses remain a major public health threat. Seasonal influenza vaccination in humans primarily stimulates pre-existing memory B cells, which differentiate into a transient wave of circulating antibody-secreting plasmablasts1–3. This recall response contributes to {\textquoteleft}original antigenic sin{\textquoteright}—the selective increase of antibody species elicited by previous exposures to influenza virus antigens4. It remains unclear whether such vaccination can also induce germinal centre reactions in the draining lymph nodes, where diversification and maturation of recruited B cells can occur5. Here we used ultrasound-guided fine needle aspiration to serially sample the draining lymph nodes and investigate the dynamics and specificity of germinal centre B cell responses after influenza vaccination in humans. Germinal centre B cells that bind to influenza vaccine could be detected as early as one week after vaccination. In three out of eight participants, we detected vaccine-binding germinal centre B cells up to nine weeks after vaccination. Between 12% and 88% of the responding germinal centre B cell clones overlapped with B cells detected among early circulating plasmablasts. These shared B cell clones had high frequencies of somatic hypermutation and encoded broadly cross-reactive monoclonal antibodies. By contrast, vaccine-induced B cell clones detected only in the germinal centre compartment exhibited significantly lower frequencies of somatic hypermutation and predominantly encoded strain-specific monoclonal antibodies, which suggests a naive B cell origin. Some of these strain-specific monoclonal antibodies recognized epitopes that were not targeted by the early plasmablast response. Thus, influenza virus vaccination in humans can elicit a germinal centre reaction that recruits B cell clones that can target new epitopes, thereby broadening the spectrum of vaccine-induced protective antibodies.",
author = "Turner, {Jackson S.} and Zhou, {Julian Q.} and Julianna Han and Schmitz, {Aaron J.} and Rizk, {Amena A.} and Alsoussi, {Wafaa B.} and Tingting Lei and Mostafa Amor and McIntire, {Katherine M.} and Philip Meade and Shirin Strohmeier and Brent, {Rafael I.} and Richey, {Sara T.} and Alem Haile and Yang, {Yuhe R.} and Klebert, {Michael K.} and Teresa Suessen and Sharlene Teefey and Presti, {Rachel M.} and Florian Krammer and Kleinstein, {Steven H.} and Ward, {Andrew B.} and Ellebedy, {Ali H.}",
note = "Funding Information: Acknowledgements We thank K. Hoehn for discussion on phylogenetic analysis, A. Boon and H. Harastani for providing A/California/04/2009 E3 (H1N1) virus; E. Lantelme for facilitating sorting; L. Kessels, M. Royal and the staff of the Infectious Diseases Clinical Research Unit at Washington University School of Medicine for assistance with vaccination and sample collection; P. G. Thomas and A. Sant for critically reading the manuscript; the Yale Center for Research Computing for use of high-performance computing infrastructure; the Genome Technology Access Center (GTAC) in the Department of Genetics at Washington University School of Medicine and the Yale Center for Genome Analysis for help with genomic analysis. The GTAC is partially supported by NCI Cancer Center Support Grant P30 CA91842 to the Siteman Cancer Center and by ICTS/CTSA Grant UL1 TR000448 from the NCRR. The Ellebedy laboratory was supported by NIAID grants R21 AI139813 and U01 AI141990, and NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400006C. The Kleinstein laboratory was supported by NIH grant R01AI10473 and HIPC-CEIRS grant U19AI089992. The Ward laboratory was supported by Collaborative Influenza Vaccine Innovation Centers contract 75N93019C00051-0-9999-1. The Krammer laboratory was supported by NIAID CEIRS contract HHSN272201400008C and NIAID grants AI117287 and AI128821. J.S.T. was supported by NIAID 5T32CA009547. J.H. was supported by NIAID 2 T32 AI007244-36. The WU321 study was reviewed and approved by the Washington University Institutional Review Board (approval no. 201808171). The manuscript was edited by the Scientific Editing Service of the Institute of Clinical and Translational Sciences at Washington University, which is supported by an NIH Clinical and Translational Science Award (UL1 TR002345). Publisher Copyright: {\textcopyright} 2020, The Author(s), under exclusive licence to Springer Nature Limited.",
year = "2020",
month = oct,
day = "1",
doi = "10.1038/s41586-020-2711-0",
language = "English",
volume = "586",
pages = "127--132",
journal = "Nature",
issn = "0028-0836",
number = "7827",
}